BQ 610

endothelin A receptor antagonist; endothelin-1 antagonist

Also Known As:

BQ-610; BQ610; hexahydroazepinocarbonyl-Leu-D-Trp(CHO)-D-Trp; hexahydroazepinocarbonyl-leucyl-tryptophyl(CHO)-tryptophan; D-Tryptophan, N-(1-formyl-N-(N-((hexahydro-1H-azepin-1-yl)carbonyl)-L-leucyl)-D-tryptophyl)-

Networked: 23 relevant articles (2 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - BQ 610: 23

Experts

1.	Ambalavanan, Namasivayam: 4 articles (05/2012 - 12/2002)
2.	Bulger, Arlene: 4 articles (05/2012 - 12/2002)
3.	Chen, Yiu-Fai: 4 articles (05/2012 - 12/2002)
4.	Oparil, Suzanne: 4 articles (05/2012 - 12/2002)
5.	Lin, Li: 3 articles (08/2008 - 08/2002)
6.	Lu, Hong: 2 articles (08/2008 - 05/2006)
7.	Murphy-Ullrich, Joanne: 2 articles (05/2007 - 05/2005)
8.	Yuan, Wen-Jun: 2 articles (05/2006 - 08/2002)
9.	James, Masheika: 1 article (05/2012)
10.	Nicola, Teodora: 1 article (05/2012)

Related Diseases

1.	Hypoxia (Hypoxemia) 08/01/2008 - "Treatment with BQ610 (5 micromol/L) significantly reduced the apoptosis rate to 13.2% +/- 3.7% (data from 4 independent experiments, p < 0.01 vs. hypoxia). " 05/01/2007 - "Newborn C57BL/6 mice (n = 6-8/gp) given either BQ610 (ET-AR blocker) or vehicle were exposed to air or hypoxia (12% O2) from birth for 1, 3, or 14 d. " 05/01/2006 - "TUNEL analysis showed that the percentage of positive apoptotic cells in BQ610 5 micromol/L group was 13.2% +/- 3.7%, significantly lower than that in hypoxia group (24.2% +/- 2.2%, P < 0.01). " 05/01/2005 - "BQ-610 prevented the hypoxia-induced increase in %WT and RV/LV thickness ratio when given from birth, and later therapy partially reversed the hypoxia-induced increase in %WT but not RV/LV thickness ratio. " 05/01/2012 - "BQ610 (but not BQ788) improved lung function, without altering alveolar development or increased TGF-β signaling in hypoxia-exposed animals. "
2.	Ischemia 02/01/1995 - "However, in hearts subjected to 15 min of ischemia followed by reperfusion, recovery of left ventricular developed pressure was improved by BQ610 pretreatment (BQ610: 52 +/- 8* mmHg, control: 24 +/- 6 mmHg). " 02/01/1995 - "In rats subjected to 30 min of no-flow ischemia, the increase of left ventricular resting pressure was significantly delayed by BQ123 and BQ610 compared to control (BQ123: 20 +/- 2* mmHg, BQ610: 19 +/- 2* mmHg, control: 44 +/- 4 mmHg at 15 min of ischemia, respectively, *P < 0.05 v control). " 02/01/1995 - "BQ123 and BQ610 delay the development of contracture during ischemia and may improve functional recovery during reperfusion. " 03/01/2000 - "Forty-five isolated rat hearts were perfused with Krebs-Henseleit buffer (KHB) for 15 min and then subjected to 0, 15, or 60 min of ischemia followed by 5 min of reperfusion with KHB, KHB + BQ-610, or KHB + BQ-123. " 04/01/1996 - "BQ610 did not affect ATP but significantly accelerated and increased creatine phosphate (51 +/- 7 vs. 37 +/- 3%) recovery on reperfusion after 30-min ischemia. "
3.	Myocardial Ischemia (Ischemic Heart Diseases) 08/01/1999 - "Acute myocardial ischemia was induced by ligation of the left anterior descending coronary artery (LAD) in 12 cats, and BQ610 was immediately injected into the occluded LAD. " 01/01/1999 - "Pretreatment with molsidomine or blockade of ETA receptors by BQ 610 can unmask the positive inotropy of ET-1 by preventing ET-induced myocardial ischemia. " 01/01/1999 - "ET-induced myocardial ischemia was abolished by molsidomine and BQ 610. " 08/01/1999 - "To observe the effects of endothelin receptor subtype A antagonist BQ610 on acute ischemic myocardial injury by electronic microscopy to study whether endogenous endothelin is involved in the pathogenesis of acute myocardial ischemia. " 02/01/1995 - "A potential detrimental role of endothelin-1 in myocardial ischemia/reperfusion injury was studied by use of the endothelin-1 antagonists BQ123 and BQ610. "
4.	Hypotension (Low Blood Pressure) 01/01/2003 - "BQ 610 does not improve hypotension or survival rates in systemic aggregated anaphylactic rabbits in vivo, implying that circulating ET-1 may not play an important role in anaphylaxis, although direct proof of production of circulating ET-1 or activation of ETA receptors is lacking in this study." 10/01/2006 - "In protocol 3, CR progressively increased with hypotension in the absence but not presence of L-NAME or BQ-610. " 01/01/2003 - "Hypotension associated with systemic aggregated anaphylaxis is not attenuated by a selective endothelin-A receptor antagonist, BQ 610, in rabbits in vivo." 10/01/2004 - "Prior antagonism of ET-1 A receptors with BQ-610 (0.5 mg/kg, i.v.) or BQ-123 (1 mg/kg, i.v.), but not ET-1B receptors with BQ-788 (0.5 mg/kg, i.v.), 60 min before the initiation of heat exposure, appreciably alleviated hyperthermia, arterial hypotension, decreased cardiac output, increment of tumor necrosis factor-alpha, and increment of cerebral ischemia (e.g., glutamate and lactate/pyruvate ratio) and injury (e.g., glycerol) markers exhibited during heatstroke. "
5.	Hypertension (High Blood Pressure) 12/01/1998 - "Concomitant administration of BQ-610 to rats fed on a fructose diet significantly reduced the hypertension. " 12/01/1998 - "In a separate experiment, BQ-610 was administered to lower the effect of ET-1 in rats with fructose-induced hypertension. " 11/01/2004 - "In the present study, BQ-610, a selective endothelin A receptor antagonist, was used to examine the role of ET-1 in insulin-induced hypertension in rats. "

Related Drugs and Biologics

1.	BQ 788
2.	cyclo(Trp-Asp-Pro-Val-Leu)
3.	Endothelins (Endothelin)
4.	Endothelin A Receptor
5.	Endothelin-1 (Endothelin 1)
6.	Endothelin Receptors (Endothelin Receptor)
7.	Insulin (Novolin)
8.	Messenger RNA (mRNA)
9.	Saline Solution
10.	Endothelin Receptor Antagonists

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation